Although second generation long-acting injectable antipsychotics (SG-LAIAs) have been approved and are widely used in adults, there is limited evidence for the use of long-acting formulations in children and adolescents. Thus, we systematically describe the off-label use of SG-LAIAs in clinical practice in adolescent inpatients.
Methods:
All individuals admitted to our Children and Adolescent Inpatient Psychiatry Unit receiving treatment with SG-LAIAs between January 2013 and June 2016 were reviewed. A retrospective analysis of medical records was conducted. Clinical diagnoses were established using DSM-5 criteria.
Results:
Thirty individuals (53.3% female) out of a total of 1,148 admitted patients (2.6%) were identified. The mean age was 16.3 (SD = 1.3; range: 12.5–17.9).The main diagnoses were psychosis (70%) and disruptive behavior disorders (DBDs) (30%), although comorbidity was frequent (96.6%), especially drug use (55.2%, mostly cannabis). SG-LAIAs used were aripiprazole (40%), risperidone (36.7%), and paliperidone palmitate (23.3%), and the main reasons were a history of low compliance (90%) and/or poor insight (73.3%). A mean improvement of 31.7 (SD = 8.7) between admission and discharge was registered in the Children's Global Assessment Scale (CGAS); no differences were observed between different SG-LAIAs. Although they were generally well tolerated, 23.3% of patients reported mild short-term side effects, which were more frequent with risperidone than with aripiprazole (p = .014).
Conclusions:
Our clinical experience suggests that SG-LAIAs may be a safe treatment option during adolescence in inpatients with psychotic disorders, as well as with DBD. No differences were found in CGAS improvement scores between the three SGA-LAIAs used, although patients on risperidone reported more side effects than those on aripiprazole. Further research is needed so as to evaluate safety and effectiveness of SG-LAIAs in this population.
Get full access to this article
View all access options for this article.
References
1.
AmadorXF, StraussDH, YaleSA, FlaumMM, EndicottJ, GormanJM: Assessment of insight in psychosis. Am J Psychiatry, 150:873–879, 1993.
2.
BaezaI, de la SernaE, Calvo-EscalonaR, MorerA, Merchán-NaranjoJ, TapiaC, Martínez-CantareroMC, AndrésP, AldaJA., SánchezB, ArangoC, Castro-FornielesJ: Antipsychotic use in children and adolescents: A 1-year follow-up study. J Clin Psychopharmacol, 34:613–619, 2014.
3.
BernardoM, BioqueM: Three-month paliperidone palmitate—A new treatment option for schizophrenia. Expert Rev Clin Pharmacol, 9:899, 2016.
4.
BoaratiMA, WangYP, Ferreira-MaiaAP, CavalcantiAR, Fu-IL: Six-month open-label follow up of risperidone long-acting injection use in pediatric bipolar disorder. Prim Care Companion CNS Disord, 15:1–8, 2013.
5.
BrissosS, VeguillaMR, TaylorD, Balanzá-MartinezV: The role of long-acting injectable antipsychotics in schizophrenia: A critical appraisal. Ther Adv Psychopharmacol, 4:198–219, 2014.
6.
CitromeL: New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev Neurother, 13:767–783, 2013.
7.
CorrellCU: Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatry, 69:26–36, 2008.
8.
CorrellCU, KratochvilCJ, MarchJ: Developments in pediatric psuchopharmacology: Focus on stimulants, antidepressants and antipsychotics. J Clin Psychiatry, 72:655–670, 2011.
9.
CrumlishN, WhittyP, ClarkeM, BrowneS, KamaliM, GervinM, McTigueO, KinsellaA, WaddingtonJL, LarkinC, O'CallaghanE: Beyond the critical period: Longitudinal study of 8-year outcome in first-episode non-affective psychosis. Br J Psychiatry, 194:18–24, 2009.
10.
CuestaMJ, PeraltaV: Lack of insight in schizophrenia. Schizophr Bull, 20:359–366, 1994.
11.
CzoborP, Van DornRA, CitromeL, KahnRS, FleischhackerWW, VolavkaJ: Treatment adherence in schizophrenia: A patient-level meta-analysis of combined CATIE and EUFEST studies. Eur Neuropsychopharmacol, 25:1158–1166, 2015.
12.
DeanAJ, McDermottBM, MarshallRT: Psychotropic medication utilization in a child and adolescent mental health service. J Child Adolesc Psychopharmacol, 16:273–285, 2006.
13.
DiomšinaB, RasmussenPD, DanilevičiuteV: Clinical experience of long-term treatment with aripiprazole (abilify) in children and adolescents at the child and adolescent psychiatric clinic 1 in Roskilde, Denmark. Acta Pol Pharm, 72:597–606, 2015.
14.
DriverDI, GogtayN, RapoportJL: Childhood onset schizophrenia and early onset schizophrenia spectrum disorders. Child Adolesc Psychiatr Clin N Am, 22:539–555, 2013.
15.
EmsleyR, ChilizaB, AsmalL: The evidence for illness progression after relapse in schizophrenia. Schizophr Res, 148:117–121, 2013.
16.
ErermisS, BildikT, TamarM, GockayA, KarasoyH, ErcanES: Zuclopenthixol-induced neuroleptic malignant síndrome in an adolescent girl. Clin Toxicol (Phila), 45:277–280, 2007.
17.
FàbregaM, SugranyesG, BaezaI: Two cases of long-acting paliperidone in adolescence. Ther Adv Psychopharmacol, 5:304–306, 2015.
18.
FindlingRL, ReedMD, O'RiordanMA, DemeterC a, StansbreyRJ, McNamaraNK: Effectiveness, safety, and pharmacokinetics of quetiapine in aggressive children with conduct disorder. J Am Acad Child Adolesc Psychiatry, 45:792–800, 2006.
19.
Fu-IL, BoaratiMA, StravogiannisA, WangYP: Use of risperidone-long-acting injection to support treatment adherence and mood stabilization in pediatric bipolar patients: Case series. J Clin Psychiatry, 70:604–606, 2009.
20.
HackS, ChowB: Pediatric psychotropic medication compliance: A literature review and research-based suggestions for improving treatment compliance. J Child Adolesc Psychopharmacol, 11:59–67, 2001.
21.
Hanssen-BauerK, HeyerdahlS, HatlingT, JensenG, OlstadP, StangelandT, TinderholtT: Admissions to acute adolescent psychiatric units: A prospective study of clinical severity and outcome. Int J Ment Health Syst, 5:1, 2011.
22.
HarmanJS, CuffelBJ, KelleherKJ: Profiling hospitals for length of stay for treatment of psychiatric disorders 2004;31:66–74. J Behav Heal Serv Res, 31:66–74, 2004.
23.
KaplanG, CasoyJ, ZummoJ: Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia. Patient Prefer Adherence, 7:1171–1180, 2013.
24.
KishimotoT, NittaM, BorensteinM, KaneJM, CorrellCU: Long-acting injectable versus oral antipsychotics for relapse prevention in schizophrenia: A meta-analysis of randomized trials. J Clin Psychiatry, 74:957–965, 2013.
25.
KowalskiJL, WinkLK, BlankenshipK, HabenichtCD, EricksonCA, StiglerKA, McDougleCJ: Paliperidone palmitate in a child with autistic disorder. J Child Adolesc Psychopharmacol, 21:491–493, 2011.
26.
KumarA, DattaSS, WrightSD, FurtadoVA, RussellPS: Atypical antipsychotics for psychosis in adolescents (Review). Cochrane Database Syst Rev, 11:1–130, 2013.
27.
LachmanA: New developments in diagnosis and treatment update: Schizophrenia/first episode psychosis in children and adolescents. J Child Adolesc Ment Health, 26:109–124, 2014.
28.
LeuchtC, HeresS, KaneJM, KisslingW, DavisJM, LeuchtS: Oral versus depot antipsychotic drugs for schizophrenia-A critical systematic review and meta-analysis of randomised long-term trials. Schizophr Res, 127:83–92, 2011.
29.
LytleS, McVoyM, SajatovicM: Long-acting injectable antipsychotics in children and adolescents. J Child Adolesc Psychopharmacol, 27:2–9, 2017.
30.
McClellanJ, StockS: Practice parameter for the assessment and treatment of children and adolescents with schizophrenia. J Am Acad Child Adolesc Psychiatry, 52:976–990, 2013.
MedeirosGC, SençoSB, LaferB, AlmeidaKM: Association between duration of untreated bipolar disorder and clinical outcome: Data from a Brazilian sample. Rev Bras Psiquiatr, 38:6–10, 2016.
33.
National Institute for Health and Care Excellence: Psychosis and schizophrenia in adults: prevention and management. NICE guideline (CG178), 2014.
34.
NormanRM, MallaAK: Examining adherence to medication and substance use as possible confounds of duration of untreated psychosis. J Nerv Ment Dis, 190:331–334, 2002.
35.
OsatukeK, CieslaJ, KasckowJW, ZisookS, MohamedS: Insight in schizophrenia: A review of etiological models and supporting research. Compr Psychiatry, 49:70–77, 2008.
36.
PappadopulosE, JensenPS, SchurSB, MacIntyreJC, KetnerS, Van OrdenK, SverdJ, SardanaS, WoodlockD, SchweitzerR, RubeD: “Real world” atypical antipsychotic prescribing practices in public child and adolescent inpatient settings. Schizophr Bull, 28:111–121, 2002.
37.
ParelladaE, BioqueM: Barriers to the use of long-acting injectable antipsychotics in the management of schizophrenia. CNS Drugs, 30:689–701, 2016.
38.
ParelladaE, VelliganDI, EmsleyR, KisslingW: Long-acting injectable antipsychotics in first-episode schizophrenia. Schizophr Res Treatment, 2012:1–3, 2012.
39.
ParelladaM, BoadaL, FraguasD, ReigS, Castro-FornielesJ, MorenoD, Gonzalez-PintoA, OteroS, Rapado-CastroM, GraellM, BaezaI, ArangoC: Trait and state attributes of insight in first episodes of early-onset schizophrenia and other psychoses: A 2-year longitudinal study. Schizophr Bull, 37:38–51, 2011.
40.
ParelladaM, FraguasD, BombínI, OteroS, Castro-FornielesJ, BaezaI, Gonzalez-PintoA, GraellM, SoutulloC, PayaB, ArangoC: Insight correlates in child- and adolescent-onset first episodes of psychosis: Results from the CAFEPS study. Psychol Med, 39:1433–1445, 2009.
41.
PatelA, MalekN, HaqF, TurnbowL, RazaS: Hirsutism in a female adolescent induced by long-acting injectable risperidone: A case report. Prim Care Companion CNS Disord, 15:1–4, 2013.
42.
PopeS, ZaraaSG: Efficacy of long-acting injectable antipsychotics in adolescents. J Child Adolesc Psychopharmacol, 26:391–394, 2016.
SavitzA, LaneR, NuamahI, GopalS, HoughD: Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: A randomized, double-blind study. J Am Acad Child Adolesc Psychiatry, 54:126–137, 2015.
45.
SchneiderC, TaylorD, ZalsmanG, FrangouS, KyriakopoulosM: Antipsychotics use in children and adolescents: An on-going challenge in clinical practice. J Psychopharmacol, 28:615–623, 2014.
46.
ShafferD, GouldMS, BrasicJ, AmbrosiniP, FisherP, BirdH, AluwahliaS: A children's global assessment scale (CGAS). Arch Gen Psychiatry, 40:1228–1231, 1983.
47.
SinghJ, RobbA, VijapurkarU, NuamahI, HoughD: A randomized, double-blind study of paliperidone extended-release in treatment of acute schizophrenia in adolescents. Biol Psychiatry, 70:1179–1187, 2011.
48.
TutkunkardasMD, AbaliO: Long acting risperidone in an adolescent with conduct disorder: A case report. Psychopharmacol Bull, 44:69–72, 2011.
49.
WinterfeldU, Le HeuzeyMF, AcquavivaE, MourenMC, BrionF, BourdonO: Psychotropic medication use in the child and adolescent psychiatry wards of a French hospital. Pharm World Sci, 30:600–604, 2008.
50.
WisniewskiA: New treatment option in resistant schizophrenia in adolescence—Case study. Eur Psychiatry, 26:368, 2011.
51.
ZhornitskyS, StipE: Oral versus long-acting injectable antipsychotics in the treatment of schizophrenia and special populations at risk for treatment nonadherence: A systematic review. Schizophr Res Treatment, 2012:407171, 2012.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
